|
Altea Therapeutics has developed an advanced drug delivery system that allows a wide variety of drugs and vaccines across the skin. This breakthrough should improve the efficacy, safety and compliance of drugs and vaccines.
Co-investors: Domain Associates, Venrock Associates, vSpring Capital
|
 |
Cameron Health is developing a novel implantable cardioverter defibrillator that is easier to implant and has no intravenous leads. Co-investors: Three Arch Partners, Versant Ventures, Delphi Ventures |
 |
Cardiocore Lab, Inc. advances the quality and speed of clinical trials by providing the world’s finest cardiac testing services. Centralized services include ECG analysis, Holter monitoring, protocol design and statistical analysis.
Co-investors: Caxton Health |
||
 |
CardioMEMS, Inc. is a medical device company that develops wireless medical pressure sensors. The technology platform is initially designed to improve the management of severe cardiovascular diseases such as heart failure and aneurysms. Co-investors: Boston Millenia, Arcapita Ventures, Foundation Medical, Easton Capital, Medtronic |
||
 |
Ception
Therapeutics, Inc. is an emerging
biopharmaceutical company discovering and
developing novel biologic and small-molecule
agents to address unmet medical needs. The
company has late-stage biologic anti-inflammatory
programs, a small molecule anti-TNF program and
several other discovery programs.
Acquired
by Cephalon Co-investors: Essex Woodlands, Investor Growth Capital, MDS, New Science Ventures, Third Point |
||
 |
Concerro
is an IT company focused on providing flexible
workforce management solutions for the healthcare
industry. The company’s lead offering is a
software system that enables facilities to create
and manage an internal registry for nurses and
other clinical staff, providing significant ROI
for the facilities and flexibility and increased
income for the staff.
Co-investors: Kaiser Ventures, Himalaya Capital, RK Ventures |
||
 |
Conor Medsystems is a medical device company that develops stents and other medical devices as delivery platforms for controlled local delivery of a wide variety of therapeutic agents. Its proprietary technologies enable the delivery of multiple drugs or biotech compounds to various sites in the body.
NASD: CONR Acquired by Johnson & Johnson Co-investors: Easton Capital, Highland Capital, Maverick Capital
|
||
 |
Interlace Medical is a
medical device company developing minimally invasive
treatment options in the field of women's health.
Co-investors: New Leaf, Spray, Baird, HLM, H&Q |
||
 |
Mako Surgical is a medical device
company that is developing advanced technologies and
procedures for the rapidly emerging orthopedic
minimally invasive total joint market.
NASD: MAKO Co-investors: MDS Capital, Skyline, Montreux, Alta, Exxel Group |
||
 |
Redpoint
Bio is a biotechnology company that has made breakthroughs in the science of taste: the elimination of the perception of bitterness and the enhancement of the sweetness of natural sugar. These breakthroughs can potentially be used extensively in the pharmaceutical and food and beverage industries. The product line will consist of natural compounds that will have their desired effects when mixed with the target products.
OTCBB: RPBC Co-investors: Cargill Ventures, NJTC Ventures, SR One |
||
 |
TherOx
developed its SuperSaturated Oxygen Therapy to treat
ischemic tissues and conditions.
Using the TherOx technology, hyperbaric levels of
oxygen can be delivered to the heart to salvage
tissue affected by acute myocardial infarction. This is the first of many
applications for TherOx’s technology platform.
Co-investors: Kleiner Perkins, DAG Ventures, Integral Capital, New Science Ventures, Wasatch Ventures |
||
 |
TransMolecular is a biotechnology company committed to discovering, developing and commercializing novel and proprietary drugs to diagnose and treat cancer and pain. TransMolecular is developing a targeted approach to treating cancer using synthetic versions of peptides isolated from natural products. The company's lead compound, targeting a deadly form of brain cancer, is in clinical trials. Co-investors: Easton Capital, MDS Capital, Tullis Dickerson, TVM Capital |